Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Collections

Filters ​

  • Focus |

    Ageing is a fundamental driver of cancer, fostering the accumulation of genetic and epigenetic changes that disrupt cellular homeostasis, promote immune system decline, alter systemic metabolism and increase cellular senescence.

    Image: L. Crow/Springer Nature Ltd.

  • Focus |

    Survival for patients with many types of malignant primary brain tumours or with brain metastasis has not improved much in the past 10 years, despite the introduction of some new treatments and despite our improved understanding of the biological bases of brain tumour development and metastasis.

    Image: Lara Crow/Springer Nature Limited

  • Focus |

    Image: Getty Images/iStockphoto Thinkstock Images \ selvanegra

  • Focus |

    This joint Focus issue from Nature Reviews CancerandNature Reviews Immunologyfeatures specially commissioned articles that discuss the promise of immunotherapy to treat cancer and how key immune cells function in the tumour microenvironment.

  • Focus |

    This Focus issue of specially-commissioned articles reflects the recent insights gained from proteomics in understanding the molecular biology of cancer, and the future promise of applying proteomics to the clinic.

  • Focus |

    Hypoxia can influence tumour formation, progression and therapy in several ways. It has, among other things, been linked to driving angiogenesis, therapeutic resistance and pathological changes to metabolic pathways. This Nature Reviews CancerCollection on Hypoxia and metabolism includes a selection of recent Reviews, Perspectives and Research Highlights that provide insight into the roles of these processes in tumour biology and therapy.

  • Focus |

    To celebrate the past 30 years of research on p53 this Focus issue of specially-commissioned articles reflects the history and emerging directions that will be important for future research on this multi-talented protein.

  • Focus |

    The resurgence of interest in the underlying processes of metastasis has led to significant new insights and translational developments. The specially commissioned articles in this Focus on Migration and metastasis discuss the new and re-emerging models and pathways that have been redefined with regard to their role in metastasis and metastasis suppression.

  • Focus |

    Although anti-angiogenesis agents targeting vascular endothelial growth factor (VEGF) pathways are already in clinical use and can effectively treat some cancers, there is a continued need for development of new angiogenesis inhibitors to circumvent resistance or reduce toxicity. Articles in this Focus issue describe some of the emerging targets for new anti-angiogenic therapies in cancer and also discuss our evolving knowledge of VEGF inhibitors based on results from the clinic.

  • Focus |

    Biomarkers are invaluable tools for cancer detection, diagnosis, patient prognosis and treatment selection. This focus discusses issues surrounding important genetic, epigenetic and protein biomarkers of cancer, including how these can be used to better understand tumour formation and to develop new therapeutic approaches.

  • Focus |

    Epigenetics — the study of heritable changes in gene expression or function that occur without a change in the DNA sequence itself — is proving to have an increasingly important role in both human development and disease, particularly cancer.

  • Focus |

    The development of cancer vaccines is not a new idea. In the late nineteenth century William Coley and colleagues observed that spontaneous tumour regression, although rare, often occurred after patients had mounted an immune response to an opportunistic infection. These ideas spawned many years of research into cancer vaccines, which, although successful in the laboratory, proved highly disappointing in the clinic.

Search

Advanced search

Quick links